---
title: "Landfar Bio-medicine Co.,Ltd (000504.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000504.SZ.md"
symbol: "000504.SZ"
name: "Landfar Bio-medicine Co.,Ltd"
industry: "Biotechnology"
datetime: "2026-05-20T19:27:43.248Z"
locales:
  - [en](https://longbridge.com/en/quote/000504.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000504.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000504.SZ.md)
---

# Landfar Bio-medicine Co.,Ltd (000504.SZ)

## Company Overview

Landfar Bio-medicine Co., Ltd operates as a biomedical technology company. It operates in two segments, Biomedicine, and Energy Saving and Environmental Protection. The Biomedicine segment engages in the provision of stem cell, immune cell storage and technical services, and medical device trade. The Energy Saving and Environmental Protection segment is involved in the external energy management contract energy management business; build-transfer business and sales of related products; and sewage treatment business.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.landfar.cn](https://www.landfar.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:11.000Z

**Overall: B (0.37)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 18 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 291.66% |  |
| Net Profit YoY | 318.45% |  |
| P/B Ratio | 10.99 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3048225231.76 |  |
| Revenue | 513699607.97 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.47% | A |
| Profit Margin | 8.22% | B |
| Gross Margin | 20.46% | D |
| Revenue YoY | 291.66% | A |
| Net Profit YoY | 318.45% | A |
| Total Assets YoY | 68.87% | A |
| Net Assets YoY | 34.09% | A |
| Cash Flow Margin | -487.83% | E |
| OCF YoY | 291.66% | A |
| Turnover | 0.63 | B |
| Gearing Ratio | 63.69% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Landfar Bio-medicine Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "291.66%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "318.45%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "10.99",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3048225231.76",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "513699607.97",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.47%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "8.22%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "20.46%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "291.66%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "318.45%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "68.87%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "34.09%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-487.83%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "291.66%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.63",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "63.69%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 73.29 | 28/81 | 74.07 | 72.66 | 71.88 |
| PB | 11.16 | 70/81 | 13.69 | 12.77 | 11.81 |
| PS (TTM) | 6.02 | 29/81 | 25.84 | 23.78 | 22.62 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000504.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000504.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000504.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000504.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**